Where to buy Enasidenib

Enasidenib (Enasidenib) is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, as determined by the U.S. Food and Drug Administration (FDA)approved IDH2 companion diagnostic test. It is an inhibitor of IDH2, and the FDA considers it a first-in-class drug. Isocitrate dehydrogenase is a key enzyme in the citric acid cycle. Mutated forms of IDH produce high levels of the (R)-enantiomer of 2-hydroxyglutarate (R-2-HG) and can promote tumor growth. IDH1 catalyzes this reaction in the cytoplasm, while IDH2 catalyzes this effect in the mitochondria. IDH2 mutations are more common than IDH1 mutations, occurring in 8% to 19% and 7% to 14% of patients with acute myeloid leukemia, respectively. Ensidipine disrupts this cycle by reducing total (R)-2-HG levels in mitochondria.

Encidipine research medicine is currently not on the market in China, nor is it covered by medical insurance. Patients cannot yet purchase this medicine through relevant domestic channels. Ensidipine is sold overseas under the trade name Idhifa. The price of the original drug is very high. The price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). The expensive price may increase the pressure on families with heavy financial burdens. Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug. For more specific prices and drug information, please consult Yaode Medical Consultant.